| 摘要 |
Disclosed is the use of a compound of formula (I) (or a pharmaceutically acceptable salt thereof) and an incretin mimetic in the manufacture of a combination for treatment of a condition selected from the group consisting of insulin resistance syndrome, diabetes, and polycystic ovary syndrome; or for the treatment or reduction in the chance of developing atherosclerosis, arteriosclerosis, obesity, hypertension, hyperlipidemia, fatty liver disease, nephropathy, neuropathy, retinopathy, foot ulceration or cataracts associated with Type II diabetes; or for the treatment of a condition selected from the group consisting of hyperlipidemia, cachexia, and obesity; wherein the incretin mimetic is selected from the group consisting of an exendin, an exendin agonist, a non-peptide small molecule GLP-1 receptor agonist, their polymer-modified and acylated forms, and pharmaceutically acceptable salts, hydrates, and solvates, and hydrates and solvates of such salts; m is 0, 2 or 4; and X is hydroxy or alkoxy; R6 is hydrogen, carbonyl or hydroxy; and three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy; or X is -NR8R9, wherein R8 is hydrogen or hydroxy and R9 is hydrogen, methyl or ethyl; R6 is hydrogen; and three of R1, R2, R3, R4 and R5 are hydrogen and the remainder are independently selected from the group consisting of hydrogen, halo, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, and perfluoromethoxy. Of particular importance is the use of compounds of general formula (I) which are selected from 4-(3-(2,6-dimethylbenzyloxy)phenyl)-4-oxobutyric acid, 3-(2,6-dimethylbenzyloxy)phenylacetic acid, 4-(3-(2,6-dimethylbenzyloxy)-phenyl)-4(R)-hydroxybutanoic acid and N-hydroxy-2-[3-(2,6-dimethylbenzyloxy)phenyl]acetamide.
|
